APO Research
Talk to an analyst

APO RESEARCH · REPORT

Musculoskeletal Disorder Stem Cell Therapy

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Musculoskeletal Disorder Stem Cell Therapy Market Analysis and Forecast 2026-2032

22 December 2025190 pages

Choose your research edition.

Industry ResearchMusculoskeletal Disorder Stem Cell Therapy Industry Research Report 2026102 pages · $2,950 USDIndustry Growth & TrendsGlobal Musculoskeletal Disorder Stem Cell Therapy Industry Growth and Trends Forecast to 203260 pages · $3,450 USDMarket StructureGlobal Musculoskeletal Disorder Stem Cell Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032176 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Musculoskeletal Disorder Stem Cell Therapy Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Musculoskeletal Disorder Stem Cell Therapy Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Musculoskeletal Disorder Stem Cell Therapy market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Musculoskeletal Disorder Stem Cell Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Musculoskeletal Disorder Stem Cell Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Musculoskeletal Disorder Stem Cell Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Musculoskeletal Disorder Stem Cell Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Musculoskeletal Disorder Stem Cell Therapy include Takeda (TiGenix), Osiris Therapeutics and NuVasive, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Musculoskeletal Disorder Stem Cell Therapy, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Musculoskeletal Disorder Stem Cell Therapy, also provides the revenue of main regions and countries. Of the upcoming market potential for Musculoskeletal Disorder Stem Cell Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Musculoskeletal Disorder Stem Cell Therapy revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Musculoskeletal Disorder Stem Cell Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Musculoskeletal Disorder Stem Cell Therapy revenue, projected growth trends, production technology, application and end-user industry.

Musculoskeletal Disorder Stem Cell Therapy Segment by Company

Takeda (TiGenix)

Osiris Therapeutics

NuVasive

Musculoskeletal Disorder Stem Cell Therapy Segment by Type

Allogeneic

Autologous

Musculoskeletal Disorder Stem Cell Therapy Segment by Application

Muscle disease

Skeletal disease

Musculoskeletal Disorder Stem Cell Therapy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Musculoskeletal Disorder Stem Cell Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Musculoskeletal Disorder Stem Cell Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Musculoskeletal Disorder Stem Cell Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Musculoskeletal Disorder Stem Cell Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Musculoskeletal Disorder Stem Cell Therapy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Musculoskeletal Disorder Stem Cell Therapy revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Musculoskeletal Disorder Stem Cell Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Allogeneic Major Player Table 3. Autologous Major Player Table 4. Global Musculoskeletal Disorder Stem Cell Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Muscle disease Major Player Table 6. Skeletal disease Major Player Table 7. Musculoskeletal Disorder Stem Cell Therapy Industry Trends Table 8. Musculoskeletal Disorder Stem Cell Therapy Industry Drivers Table 9. Musculoskeletal Disorder Stem Cell Therapy Industry Opportunities and Challenges Table 10. Musculoskeletal Disorder Stem Cell Therapy Industry Restraints Table 11. Global Musculoskeletal Disorder Stem Cell Therapy Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 12. Global Musculoskeletal Disorder Stem Cell Therapy Market Size by Region (2021-2026) & (US$ Million) Table 13. Global Musculoskeletal Disorder Stem Cell Therapy Market Share by Region (2021-2026) Table 14. Global Musculoskeletal Disorder Stem Cell Therapy Market Size by Region (2027-2032) & (US$ Million) Table 15. Global Musculoskeletal Disorder Stem Cell Therapy Market Share by Region (2027-2032) Table 16. Global Musculoskeletal Disorder Stem Cell Therapy Revenue by Players (US$ Million) & (2021-2026) Table 17. Global Musculoskeletal Disorder Stem Cell Therapy Revenue Market Share by Players (2021-2026) Table 18. Global Musculoskeletal Disorder Stem Cell Therapy Key Players Ranking, 2024 VS 2025 VS 2026 Table 19. Global Musculoskeletal Disorder Stem Cell Therapy Key Players Headquarters & Area Served Table 20. Global Musculoskeletal Disorder Stem Cell Therapy Players, Product Type & Application Table 21. Global Musculoskeletal Disorder Stem Cell Therapy Players Establishment Date Table 22. Global Players Market Concentration Ratio (CR5 and HHI) Table 23. Global Musculoskeletal Disorder Stem Cell Therapy by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 24. Global Musculoskeletal Disorder Stem Cell Therapy Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Musculoskeletal Disorder Stem Cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 26. Global Musculoskeletal Disorder Stem Cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 27. Global Musculoskeletal Disorder Stem Cell Therapy Revenue Market Share by Type (2021-2026) Table 28. Global Musculoskeletal Disorder Stem Cell Therapy Revenue Market Share by Type (2027-2032) Table 29. Global Musculoskeletal Disorder Stem Cell Therapy Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Musculoskeletal Disorder Stem Cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 31. Global Musculoskeletal Disorder Stem Cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 32. Global Musculoskeletal Disorder Stem Cell Therapy Revenue Market Share by Application (2021-2026) Table 33. Global Musculoskeletal Disorder Stem Cell Therapy Revenue Market Share by Application (2027-2032) Table 34. Takeda (TiGenix) Company Information Table 35. Takeda (TiGenix) Business Overview Table 36. Takeda (TiGenix) Musculoskeletal Disorder Stem Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Takeda (TiGenix) Musculoskeletal Disorder Stem Cell Therapy Product Portfolio Table 38. Takeda (TiGenix) Recent Development Table 39. Osiris Therapeutics Company Information Table 40. Osiris Therapeutics Business Overview Table 41. Osiris Therapeutics Musculoskeletal Disorder Stem Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Osiris Therapeutics Musculoskeletal Disorder Stem Cell Therapy Product Portfolio Table 43. Osiris Therapeutics Recent Development Table 44. NuVasive Company Information Table 45. NuVasive Business Overview Table 46. NuVasive Musculoskeletal Disorder Stem Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. NuVasive Musculoskeletal Disorder Stem Cell Therapy Product Portfolio Table 48. NuVasive Recent Development Table 49. North America Musculoskeletal Disorder Stem Cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 50. North America Musculoskeletal Disorder Stem Cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 51. North America Musculoskeletal Disorder Stem Cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 52. North America Musculoskeletal Disorder Stem Cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 53. North America Musculoskeletal Disorder Stem Cell Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 54. North America Musculoskeletal Disorder Stem Cell Therapy Revenue by Country (2021-2026) & (US$ Million) Table 55. North America Musculoskeletal Disorder Stem Cell Therapy Revenue by Country (US$ Million) & (2027-2032) Table 56. Europe Musculoskeletal Disorder Stem Cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 57. Europe Musculoskeletal Disorder Stem Cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 58. Europe Musculoskeletal Disorder Stem Cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 59. Europe Musculoskeletal Disorder Stem Cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 60. Europe Musculoskeletal Disorder Stem Cell Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 61. Europe Musculoskeletal Disorder Stem Cell Therapy Revenue by Country (2021-2026) & (US$ Million) Table 62. Europe Musculoskeletal Disorder Stem Cell Therapy Revenue by Country (US$ Million) & (2027-2032) Table 63. China Musculoskeletal Disorder Stem Cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 64. China Musculoskeletal Disorder Stem Cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 65. China Musculoskeletal Disorder Stem Cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 66. China Musculoskeletal Disorder Stem Cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 67. Asia Musculoskeletal Disorder Stem Cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 68. Asia Musculoskeletal Disorder Stem Cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 69. Asia Musculoskeletal Disorder Stem Cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 70. Asia Musculoskeletal Disorder Stem Cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 71. Asia Musculoskeletal Disorder Stem Cell Therapy Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 72. Asia Musculoskeletal Disorder Stem Cell Therapy Revenue by Region (US$ Million) & (2021-2026) Table 73. Asia Musculoskeletal Disorder Stem Cell Therapy Revenue by Region (US$ Million) & (2027-2032) Table 74. SAMEA Musculoskeletal Disorder Stem Cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 75. SAMEA Musculoskeletal Disorder Stem Cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 76. SAMEA Musculoskeletal Disorder Stem Cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 77. SAMEA Musculoskeletal Disorder Stem Cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 78. SAMEA Musculoskeletal Disorder Stem Cell Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 79. SAMEA Musculoskeletal Disorder Stem Cell Therapy Revenue by Country (2021-2026) & (US$ Million) Table 80. SAMEA Musculoskeletal Disorder Stem Cell Therapy Revenue by Country (US$ Million) & (2027-2032) Table 81. Research Programs/Design for This Report Table 82. Authors List of This Report Table 83. Secondary Sources Table 84. Primary Sources List of Figures Figure 1. Musculoskeletal Disorder Stem Cell Therapy Image Figure 2. Global Musculoskeletal Disorder Stem Cell Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Musculoskeletal Disorder Stem Cell Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 4. Allogeneic Image Figure 5. Autologous Image Figure 6. Global Musculoskeletal Disorder Stem Cell Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Musculoskeletal Disorder Stem Cell Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 8. Muscle disease Image Figure 9. Skeletal disease Image Figure 10. Global Musculoskeletal Disorder Stem Cell Therapy Market Size (US$ Million) & (2021-2032) Figure 11. Global Musculoskeletal Disorder Stem Cell Therapy Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Musculoskeletal Disorder Stem Cell Therapy Market Share by Region: 2021 VS 2025 VS 2032 Figure 13. Global Musculoskeletal Disorder Stem Cell Therapy Players Revenue Share Top 10 and Top 5 in 2025 Figure 14. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 15. Global Musculoskeletal Disorder Stem Cell Therapy Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Musculoskeletal Disorder Stem Cell Therapy Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Musculoskeletal Disorder Stem Cell Therapy Revenue Market Share by Type (2021-2032) Figure 18. Global Musculoskeletal Disorder Stem Cell Therapy Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Musculoskeletal Disorder Stem Cell Therapy Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 20. Global Musculoskeletal Disorder Stem Cell Therapy Revenue Market Share by Application (2021-2032) Figure 21. North America Musculoskeletal Disorder Stem Cell Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 22. North America Musculoskeletal Disorder Stem Cell Therapy Revenue Share by Type (2021-2032) Figure 23. North America Musculoskeletal Disorder Stem Cell Therapy Revenue Share by Application (2021-2032) Figure 24. North America Musculoskeletal Disorder Stem Cell Therapy Revenue Share by Country (2021-2032) Figure 25. United States Musculoskeletal Disorder Stem Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 26. Canada Musculoskeletal Disorder Stem Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Mexico Musculoskeletal Disorder Stem Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Europe Musculoskeletal Disorder Stem Cell Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. Europe Musculoskeletal Disorder Stem Cell Therapy Revenue Share by Type (2021-2032) Figure 30. Europe Musculoskeletal Disorder Stem Cell Therapy Revenue Share by Application (2021-2032) Figure 31. Europe Musculoskeletal Disorder Stem Cell Therapy Revenue Share by Country (2021-2032) Figure 32. Germany Musculoskeletal Disorder Stem Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. France Musculoskeletal Disorder Stem Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. U.K. Musculoskeletal Disorder Stem Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Italy Musculoskeletal Disorder Stem Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Spain Musculoskeletal Disorder Stem Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Russia Musculoskeletal Disorder Stem Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Netherlands Musculoskeletal Disorder Stem Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Nordic Countries Musculoskeletal Disorder Stem Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. China Musculoskeletal Disorder Stem Cell Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 41. China Musculoskeletal Disorder Stem Cell Therapy Revenue Share by Type (2021-2032) Figure 42. China Musculoskeletal Disorder Stem Cell Therapy Revenue Share by Application (2021-2032) Figure 43. Asia Musculoskeletal Disorder Stem Cell Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. Asia Musculoskeletal Disorder Stem Cell Therapy Revenue Share by Type (2021-2032) Figure 45. Asia Musculoskeletal Disorder Stem Cell Therapy Revenue Share by Application (2021-2032) Figure 46. Asia Musculoskeletal Disorder Stem Cell Therapy Revenue Share by Region (2021-2032) Figure 47. Japan Musculoskeletal Disorder Stem Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. South Korea Musculoskeletal Disorder Stem Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. India Musculoskeletal Disorder Stem Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. Australia Musculoskeletal Disorder Stem Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Taiwan Musculoskeletal Disorder Stem Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Southeast Asia Musculoskeletal Disorder Stem Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. SAMEA Musculoskeletal Disorder Stem Cell Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 54. SAMEA Musculoskeletal Disorder Stem Cell Therapy Revenue Share by Type (2021-2032) Figure 55. SAMEA Musculoskeletal Disorder Stem Cell Therapy Revenue Share by Application (2021-2032) Figure 56. SAMEA Musculoskeletal Disorder Stem Cell Therapy Revenue Share by Country (2021-2032) Figure 57. Brazil Musculoskeletal Disorder Stem Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Argentina Musculoskeletal Disorder Stem Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Chile Musculoskeletal Disorder Stem Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Colombia Musculoskeletal Disorder Stem Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Peru Musculoskeletal Disorder Stem Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Saudi Arabia Musculoskeletal Disorder Stem Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Israel Musculoskeletal Disorder Stem Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. UAE Musculoskeletal Disorder Stem Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Turkey Musculoskeletal Disorder Stem Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Iran Musculoskeletal Disorder Stem Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Egypt Musculoskeletal Disorder Stem Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Years Considered Figure 69. Research Process Figure 70. Key Executives Interviewed

Scope & coverage.

Types
  • Allogeneic
  • Autologous
Applications
  • Muscle disease
  • Skeletal disease
Companies covered
  • Takeda (TiGenix)
  • Osiris Therapeutics
  • NuVasive

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Musculoskeletal Disorder Stem Cell Therapy Market by Type
  3. 1.2.1 Global Musculoskeletal Disorder Stem Cell Therapy Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Allogeneic
  5. 1.2.3 Autologous
  6. 1.3 Musculoskeletal Disorder Stem Cell Therapy Market by Application
  7. 1.3.1 Global Musculoskeletal Disorder Stem Cell Therapy Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Muscle disease
  9. 1.3.3 Skeletal disease
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Musculoskeletal Disorder Stem Cell Therapy Market Dynamics
  1. 2.1 Musculoskeletal Disorder Stem Cell Therapy Industry Trends
  2. 2.2 Musculoskeletal Disorder Stem Cell Therapy Industry Drivers
  3. 2.3 Musculoskeletal Disorder Stem Cell Therapy Industry Opportunities and Challenges
  4. 2.4 Musculoskeletal Disorder Stem Cell Therapy Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Musculoskeletal Disorder Stem Cell Therapy Market Perspective (2021-2032)
  2. 3.2 Global Musculoskeletal Disorder Stem Cell Therapy Growth Trends by Region
  3. 3.2.1 Global Musculoskeletal Disorder Stem Cell Therapy Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Musculoskeletal Disorder Stem Cell Therapy Market Size by Region (2021-2026)
  5. 3.2.3 Global Musculoskeletal Disorder Stem Cell Therapy Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Musculoskeletal Disorder Stem Cell Therapy Revenue by Players
  2. 4.1.1 Global Musculoskeletal Disorder Stem Cell Therapy Revenue by Players (2021-2026)
  3. 4.1.2 Global Musculoskeletal Disorder Stem Cell Therapy Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Musculoskeletal Disorder Stem Cell Therapy Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Musculoskeletal Disorder Stem Cell Therapy Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Musculoskeletal Disorder Stem Cell Therapy Key Players Headquarters & Area Served
  7. 4.4 Global Musculoskeletal Disorder Stem Cell Therapy Players, Product Type & Application
  8. 4.5 Global Musculoskeletal Disorder Stem Cell Therapy Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Musculoskeletal Disorder Stem Cell Therapy Market CR5 and HHI
  11. 4.6.3 2025 Musculoskeletal Disorder Stem Cell Therapy Tier 1, Tier 2, and Tier 3
5 Musculoskeletal Disorder Stem Cell Therapy Market Size by Type
  1. 5.1 Global Musculoskeletal Disorder Stem Cell Therapy Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Musculoskeletal Disorder Stem Cell Therapy Revenue by Type (2021-2032)
  3. 5.3 Global Musculoskeletal Disorder Stem Cell Therapy Revenue Market Share by Type (2021-2032)
6 Musculoskeletal Disorder Stem Cell Therapy Market Size by Application
  1. 6.1 Global Musculoskeletal Disorder Stem Cell Therapy Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Musculoskeletal Disorder Stem Cell Therapy Revenue by Application (2021-2032)
  3. 6.3 Global Musculoskeletal Disorder Stem Cell Therapy Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Takeda (TiGenix)
  2. 7.1.1 Takeda (TiGenix) Company Information
  3. 7.1.2 Takeda (TiGenix) Business Overview
  4. 7.1.3 Takeda (TiGenix) Musculoskeletal Disorder Stem Cell Therapy Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Takeda (TiGenix) Musculoskeletal Disorder Stem Cell Therapy Product Portfolio
  6. 7.1.5 Takeda (TiGenix) Recent Developments
  7. 7.2 Osiris Therapeutics
  8. 7.2.1 Osiris Therapeutics Company Information
  9. 7.2.2 Osiris Therapeutics Business Overview
  10. 7.2.3 Osiris Therapeutics Musculoskeletal Disorder Stem Cell Therapy Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Osiris Therapeutics Musculoskeletal Disorder Stem Cell Therapy Product Portfolio
  12. 7.2.5 Osiris Therapeutics Recent Developments
  13. 7.3 NuVasive
  14. 7.3.1 NuVasive Company Information
  15. 7.3.2 NuVasive Business Overview
  16. 7.3.3 NuVasive Musculoskeletal Disorder Stem Cell Therapy Revenue and Gross Margin (2021-2026)
  17. 7.3.4 NuVasive Musculoskeletal Disorder Stem Cell Therapy Product Portfolio
  18. 7.3.5 NuVasive Recent Developments
8 North America
  1. 8.1 North America Musculoskeletal Disorder Stem Cell Therapy Revenue (2021-2032)
  2. 8.2 North America Musculoskeletal Disorder Stem Cell Therapy Revenue by Type (2021-2032)
  3. 8.2.1 North America Musculoskeletal Disorder Stem Cell Therapy Revenue by Type (2021-2026)
  4. 8.2.2 North America Musculoskeletal Disorder Stem Cell Therapy Revenue by Type (2027-2032)
  5. 8.3 North America Musculoskeletal Disorder Stem Cell Therapy Revenue Share by Type (2021-2032)
  6. 8.4 North America Musculoskeletal Disorder Stem Cell Therapy Revenue by Application (2021-2032)
  7. 8.4.1 North America Musculoskeletal Disorder Stem Cell Therapy Revenue by Application (2021-2026)
  8. 8.4.2 North America Musculoskeletal Disorder Stem Cell Therapy Revenue by Application (2027-2032)
  9. 8.5 North America Musculoskeletal Disorder Stem Cell Therapy Revenue Share by Application (2021-2032)
  10. 8.6 North America Musculoskeletal Disorder Stem Cell Therapy Revenue by Country
  11. 8.6.1 North America Musculoskeletal Disorder Stem Cell Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Musculoskeletal Disorder Stem Cell Therapy Revenue by Country (2021-2026)
  13. 8.6.3 North America Musculoskeletal Disorder Stem Cell Therapy Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Musculoskeletal Disorder Stem Cell Therapy Revenue (2021-2032)
  2. 9.2 Europe Musculoskeletal Disorder Stem Cell Therapy Revenue by Type (2021-2032)
  3. 9.2.1 Europe Musculoskeletal Disorder Stem Cell Therapy Revenue by Type (2021-2026)
  4. 9.2.2 Europe Musculoskeletal Disorder Stem Cell Therapy Revenue by Type (2027-2032)
  5. 9.3 Europe Musculoskeletal Disorder Stem Cell Therapy Revenue Share by Type (2021-2032)
  6. 9.4 Europe Musculoskeletal Disorder Stem Cell Therapy Revenue by Application (2021-2032)
  7. 9.4.1 Europe Musculoskeletal Disorder Stem Cell Therapy Revenue by Application (2021-2026)
  8. 9.4.2 Europe Musculoskeletal Disorder Stem Cell Therapy Revenue by Application (2027-2032)
  9. 9.5 Europe Musculoskeletal Disorder Stem Cell Therapy Revenue Share by Application (2021-2032)
  10. 9.6 Europe Musculoskeletal Disorder Stem Cell Therapy Revenue by Country
  11. 9.6.1 Europe Musculoskeletal Disorder Stem Cell Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Musculoskeletal Disorder Stem Cell Therapy Revenue by Country (2021-2026)
  13. 9.6.3 Europe Musculoskeletal Disorder Stem Cell Therapy Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Musculoskeletal Disorder Stem Cell Therapy Revenue (2021-2032)
  2. 10.2 China Musculoskeletal Disorder Stem Cell Therapy Revenue by Type (2021-2032)
  3. 10.2.1 China Musculoskeletal Disorder Stem Cell Therapy Revenue by Type (2021-2026)
  4. 10.2.2 China Musculoskeletal Disorder Stem Cell Therapy Revenue by Type (2027-2032)
  5. 10.3 China Musculoskeletal Disorder Stem Cell Therapy Revenue Share by Type (2021-2032)
  6. 10.4 China Musculoskeletal Disorder Stem Cell Therapy Revenue by Application (2021-2032)
  7. 10.4.1 China Musculoskeletal Disorder Stem Cell Therapy Revenue by Application (2021-2026)
  8. 10.4.2 China Musculoskeletal Disorder Stem Cell Therapy Revenue by Application (2027-2032)
  9. 10.5 China Musculoskeletal Disorder Stem Cell Therapy Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Musculoskeletal Disorder Stem Cell Therapy Revenue (2021-2032)
  2. 11.2 Asia Musculoskeletal Disorder Stem Cell Therapy Revenue by Type (2021-2032)
  3. 11.2.1 Asia Musculoskeletal Disorder Stem Cell Therapy Revenue by Type (2021-2026)
  4. 11.2.2 Asia Musculoskeletal Disorder Stem Cell Therapy Revenue by Type (2027-2032)
  5. 11.3 Asia Musculoskeletal Disorder Stem Cell Therapy Revenue Share by Type (2021-2032)
  6. 11.4 Asia Musculoskeletal Disorder Stem Cell Therapy Revenue by Application (2021-2032)
  7. 11.4.1 Asia Musculoskeletal Disorder Stem Cell Therapy Revenue by Application (2021-2026)
  8. 11.4.2 Asia Musculoskeletal Disorder Stem Cell Therapy Revenue by Application (2027-2032)
  9. 11.5 Asia Musculoskeletal Disorder Stem Cell Therapy Revenue Share by Application (2021-2032)
  10. 11.6 Asia Musculoskeletal Disorder Stem Cell Therapy Revenue by Country
  11. 11.6.1 Asia Musculoskeletal Disorder Stem Cell Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Musculoskeletal Disorder Stem Cell Therapy Revenue by Country (2021-2026)
  13. 11.6.3 Asia Musculoskeletal Disorder Stem Cell Therapy Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Musculoskeletal Disorder Stem Cell Therapy Revenue (2021-2032)
  2. 12.2 SAMEA Musculoskeletal Disorder Stem Cell Therapy Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Musculoskeletal Disorder Stem Cell Therapy Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Musculoskeletal Disorder Stem Cell Therapy Revenue by Type (2027-2032)
  5. 12.3 SAMEA Musculoskeletal Disorder Stem Cell Therapy Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Musculoskeletal Disorder Stem Cell Therapy Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Musculoskeletal Disorder Stem Cell Therapy Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Musculoskeletal Disorder Stem Cell Therapy Revenue by Application (2027-2032)
  9. 12.5 SAMEA Musculoskeletal Disorder Stem Cell Therapy Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Musculoskeletal Disorder Stem Cell Therapy Revenue by Country
  11. 12.6.1 SAMEA Musculoskeletal Disorder Stem Cell Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Musculoskeletal Disorder Stem Cell Therapy Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Musculoskeletal Disorder Stem Cell Therapy Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst